- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01075412
FLT PET Imaging for Cervical Cancer
'F-18 Fluorothymidine ([18F]FLT) PET Imaging for Early Evaluation of Response to Chemoradiation Therapy in Patients With Cervical Cancer
Our primary hypothesis is that [18F]FLT PET can identify active bone marrow in addition to metabolically active tumor.
This trial will use FLT-PET imaging to define areas of active bone marrow in the pelvis. The radiation plan is then designed to spare that area, in hopes of keeping the bone marrow active during therapy. Bone marrow and tumor activity will be monitored using a sequence of FLT PET scans during the course of chemotherapy and radiation therapy.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Subjects will undergo a total of up to 5 FLT PET scans.
Subjects are randomized between two groups to reduce radiation exposure from the FLT PET scans. If bone marrow activity is not identified in one scan, further scans are cancelled until the 1-month follow up scan. This is not a randomization to compare therapeutic efficacy between two study arms. Data will be pooled for analysis as pre-specified in the study's statistical plan.
Group 1 has FLT PET scans pretreatment, after 5 radiation treatments, after 10 radiation treatments, after 15 radiation treatments, and then 1 month after completing radiation therapy.
Group 2 has FLT PET scans pretreatment, after 5 radiation treatments, after 10 radiation treatments, after 20 radiation treatments, and then 1 month after completing radiation therapy.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Holden Comprehensive Cancer Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Ability to understand and willingness to sign a written informed consent document.
- Histologically confirmed stage IB2, IIA, IIB, IIIB, and IVA squamous cell carcinoma of the cervix.
- Scheduled to receive chemo-radiation for oncologic treatment.
- Karnofsky of at least 60 at time of screening
- Life expectancy of at least 6 months.
- Leukocytes at least 3,000/microL
- absolute neutrophil count at least 1,500/microL
- platelets at least 100,000/microL
- total bilirubin at maximum 1.0 mg/dL (UIHC limit of normal)
- either ALT or AST less than 2.5 times the upper limit of normal
- creatinine less than 1.5 times the upper limit of normal
- non-pregnant, non-nursing, willing to use contraception
Exclusion Criteria:
- oncology research protocol requiring full pelvic radiation (i.e., 4-field box technique) or experimental chemotherapy
- uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements.
- subjects taking nucleoside analog medications such as those used as antiretroviral agents.
- patients who have undergone hysterectomy or will have a hysterectomy as part of their cancer therapy.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Group 2
Receives fourth [F18]Fluorothymidine (FLT) PET scan after 20 fractions of radiation therapy.
|
FLT PET scan 5 mCi (+/- 10%)
Outros nomes:
|
Experimental: Group 1
Receives fourth [F18]Fluorothymidine (FLT) PET scan after 15 fractions of radiation therapy.
|
FLT PET scan 5 mCi (+/- 10%)
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Percent Difference From Baseline IMRT Plan (%)
Prazo: Baseline (pre-treatment)
|
The difference in volume of bone marrow receiving radiation using a bone-marrow-sparing radiation plan compared to a standard radiation plan (IMRT), expressed as a percentage.
Both plans are patient-specific.
Bone-marrow is identified using the baseline FLT PET/CT obtained pre-imaging.
Active bone marrow is considered to have an uptake value (SUV) of 2, 3, or 4. The standard IMRT plan was created using the criteria of the National Cancer Institute's Radiation Therapy Oncology Group study RTOG-0418.
Radiation dose bins evaluated are 5 Gray, 10 Gray, 20 Gray, and 30 Gray.
The change in dose to tumor is also provided.
A negative value indicates that more bone marrow or tissue was spared using the bone-marrow sparing plan.
|
Baseline (pre-treatment)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Chemotherapy Compliance
Prazo: post-treatment
|
The number of participants who missed at least one prescribed chemotherapy administration due to low blood counts.
|
post-treatment
|
Number of Participants With Standardized Toxicity Severity Grades for White Blood Cell Counts
Prazo: baseline, weekly during radiation treatment for up to 5 weeks, and 30 days post treatment
|
White blood cell counts measurements expressed in standardized toxicity severity grades (Common Terminology Criteria for Adverse Events, v4.03) measured weekly during combined chemotherapy and radiation therapy treatment and then once at 30 day follow-up and at 1 year follow-up
|
baseline, weekly during radiation treatment for up to 5 weeks, and 30 days post treatment
|
Number of Participants With Standardized Toxicity Severity Grades for Decreased Platelet Counts.
Prazo: baseline, weekly during radiation treatment for up to 5 weeks, and 30 days post treatment
|
Platelet cell counts measurements expressed in standardized toxicity severity grades (Common Terminology Criteria for Adverse Events, v4.03) measured once weekly during combined chemotherapy and radiation therapy, then once at 30 day follow-up, and once at 1 year follow-up
|
baseline, weekly during radiation treatment for up to 5 weeks, and 30 days post treatment
|
Number of Participants With Standardized Toxicity Severity Grades for Decreased Absolute Neutrophil Counts (ANCs)
Prazo: baseline, weekly during radiation treatment for up to 5 weeks, and 30 days post treatment
|
Absolute neutrophil counts (ANCs) measurements expressed in standardized toxicity severity grades (Common Terminology Criteria for Adverse Events, v4.03) measured once weekly during combined chemotherapy and radiation therapy, then once at 30 day follow-up, and once at 1 year follow-up.
|
baseline, weekly during radiation treatment for up to 5 weeks, and 30 days post treatment
|
Number of Participants With Standardized Toxicity Severity Grades for Decreased Lymphocyte Counts.
Prazo: baseline, weekly during radiation treatment for up to 5 weeks, and 30 days post treatment
|
Lymphocyte counts measurements expressed in standardized toxicity severity grades (Common Terminology Criteria for Adverse Events, v4.03) measured once weekly during combined chemotherapy and radiation therapy, then once at 30 day follow-up, and once at 1 year follow-up
|
baseline, weekly during radiation treatment for up to 5 weeks, and 30 days post treatment
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Michael M Graham, Ph.D., M.D., University of Iowa
- Investigador principal: Sarah McGuire, Ph.D., University of Iowa
Publicações e links úteis
Publicações Gerais
- McGuire SM, Menda Y, Ponto LL, Gross B, Juweid M, Bayouth JE. A methodology for incorporating functional bone marrow sparing in IMRT planning for pelvic radiation therapy. Radiother Oncol. 2011 Apr;99(1):49-54. doi: 10.1016/j.radonc.2011.01.025. Epub 2011 Mar 22.
- McGuire SM, Menda Y, Boles Ponto LL, Gross B, Buatti J, Bayouth JE. 3'-deoxy-3'-[(1)(8)F]fluorothymidine PET quantification of bone marrow response to radiation dose. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):888-93. doi: 10.1016/j.ijrobp.2010.12.009. Epub 2011 Feb 6. Erratum In: Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):7.
- Menda Y, Ponto LL, Dornfeld KJ, Tewson TJ, Watkins GL, Gupta AK, Anderson C, McGuire S, Schultz MK, Sunderland JJ, Graham MM, Buatti JM. Investigation of the pharmacokinetics of 3'-deoxy-3'-[18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer. Nucl Med Biol. 2010 May;37(4):433-8. doi: 10.1016/j.nucmedbio.2010.02.005.
- McGuire SM, Bhatia SK, Sun W, Jacobson GM, Menda Y, Ponto LL, Smith BJ, Gross BA, Bayouth JE, Sunderland JJ, Graham MM, Buatti JM. Using [(18)F]Fluorothymidine Imaged With Positron Emission Tomography to Quantify and Reduce Hematologic Toxicity Due to Chemoradiation Therapy for Pelvic Cancer Patients. Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):228-39. doi: 10.1016/j.ijrobp.2016.04.009. Epub 2016 Apr 19.
- McGuire SM, Menda Y, Ponto LLB, Gross B, TenNapel M, Smith BJ, Bayouth JE. Spatial mapping of functional pelvic bone marrow using FLT PET. J Appl Clin Med Phys. 2014 Jul 8;15(4):129-136. doi: 10.1120/jacmp.v15i4.4780.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 200906786
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Neoplasias do colo uterino
-
Stanford UniversityConcluídoCirurgia Cervical Posterior | Fusão Cervical Posterior | Laminectomia cervical posterior | Laminoplastia Cervical PosteriorEstados Unidos
-
M.D. Anderson Cancer CenterRetiradoCâncer cervical estágio IB3 FIGO 2018 | Câncer Cervical Estágio II FIGO 2018 | Câncer Cervical Estágio IIA FIGO 2018 | Câncer Cervical Estágio IIA1 FIGO 2018 | Câncer Cervical Estágio IIA2 FIGO 2018 | Câncer Cervical Estágio IIB FIGO 2018 | Câncer cervical estágio III FIGO 2018 | Câncer cervical estágio... e outras condições
-
Mayo ClinicNational Cancer Institute (NCI)RecrutamentoCarcinoma Adenoescamoso Cervical | Carcinoma Espinocelular Cervical Sem Outra Especificação | Carcinoma Cervical Recorrente | Câncer cervical estágio IB3 FIGO 2018 | Câncer Cervical Estágio II FIGO 2018 | Câncer Cervical Estágio IIA FIGO 2018 | Câncer Cervical Estágio IIA1 FIGO 2018 | Câncer Cervical... e outras condiçõesEstados Unidos
-
Gazi UniversityRecrutamentoRadiculopatia Cervical | Dor Radicular Cervical | Radiculite Cervical | Síndrome da raiz cervicalPeru
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Ativo, não recrutandoCarcinoma de células escamosas cervical localmente avançado, sem outra especificação | Câncer cervical estágio IB3 FIGO 2018 | Câncer Cervical Estágio II FIGO 2018 | Câncer Cervical Estágio IIA FIGO 2018 | Câncer Cervical Estágio IIA1 FIGO 2018 | Câncer Cervical Estágio IIA2 FIGO 2018 | Câncer Cervical... e outras condiçõesEstados Unidos
-
National Cancer Institute (NCI)NRG OncologyAtivo, não recrutandoAdenocarcinoma Cervical | Carcinoma Adenoescamoso Cervical | Carcinoma Espinocelular Cervical | Câncer cervical estágio IB2 AJCC v8 | Câncer Cervical Estágio II AJCC v8 | Câncer cervical estágio IIA AJCC v8 | Câncer cervical estágio IIA1 AJCC v8 | Câncer cervical estágio IIA2 AJCC v8 | Câncer cervical... e outras condiçõesEstados Unidos
-
M.D. Anderson Cancer CenterRecrutamentoCarcinoma Neuroendócrino de Células Grandes Cervicais | Carcinoma Neuroendócrino Cervical | Carcinoma Cervical de Pequenas Células | Carcinoma Indiferenciado Cervical | Câncer Cervical Estágio I AJCC v8 | Câncer Cervical Estágio IA AJCC v8 | Câncer cervical estágio IA1 AJCC v8 | Câncer cervical estágio... e outras condiçõesEstados Unidos
-
Valérie SchuermansRecrutamentoDoença do Disco Cervical | Fusão Cervical | Fusão da Coluna Vertebral | Espondilose cervical | Hérnia de Disco Cervical | Mielopatia Cervical | Degeneração do Disco Cervical | Radiculopatia Cervical | Mielopatia Compressiva | Radiculopatia, Região Cervical | Radiculopatia; na espondilose | Radiculopatia; no Distúrbio... e outras condiçõesHolanda
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Ativo, não recrutandoAdenocarcinoma Cervical | Carcinoma Adenoescamoso Cervical | Carcinoma Espinocelular Cervical Sem Outra Especificação | Câncer cervical estágio IB3 FIGO 2018 | Câncer Cervical Estágio II FIGO 2018 | Câncer Cervical Estágio IIA FIGO 2018 | Câncer Cervical Estágio IIA1 FIGO 2018 | Câncer Cervical Estágio... e outras condiçõesEstados Unidos
-
University of AarhusDesconhecidoCâncer cervical | Câncer de colo do útero | Displasia Cervical | Lesão Cervical | Neoplasia Cervical | Doença cervicalDinamarca
Ensaios clínicos em [F18]Fluorothymidine
-
Johns Hopkins UniversityNational Institute on Aging (NIA)RetiradoSaudável | Doença de AlzheimerEstados Unidos
-
Assistance Publique Hopitaux De MarseilleDesconhecido
-
Siemens Molecular ImagingRescindidoCâncer de mamaEstados Unidos
-
Avid RadiopharmaceuticalsConcluídoDoença de AlzheimerEstados Unidos
-
Chang Gung Memorial HospitalDesconhecido
-
Avid RadiopharmaceuticalsConcluídoDegeneração corticobasal | Paralisia Supranuclear ProgressivaEstados Unidos
-
Lantheus Medical ImagingRetiradoDoença arterial coronária
-
National Cancer Institute (NCI)Recrutamento
-
Eli Lilly and CompanyAinda não está recrutandoDoença de AlzheimerEstados Unidos, Reino Unido, Japão
-
M.D. Anderson Cancer CenterLantheus Medical ImagingRecrutamentoCâncer de mama | Carcinoma hepatocelular | Câncer de pâncreasEstados Unidos